Rishi K Patel, Francesco Bandera, Lucia Venneri, Aldostefano Porcari, Yousuf Razvi, Adam Ioannou, Liza Chacko, Ana Martinez-Naharro, Muhammad U Rauf, Daniel Knight, James Brown, Aviva Petrie, Ashutosh Wechalekar, Carol Whelan, Helen Lachmann, Vivek Muthurangu, Marco Guazzi, Philip N Hawkins, Julian D Gillmore, Marianna Fontana
IMPORTANCE: Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking in patients with transthyretin (ATTR) amyloidosis. OBJECTIVE: To use CPET to characterize the spectrum of functional phenotypes in patients with ATTR amyloidosis and assess their association with the cardiac amyloid burden as well as the association between CPET parameters and prognosis. DESIGN, SETTING AND PARTICIPANTS: This single-center study evaluated patients diagnosed with ATTR amyloidosis from May 2019 to September 2022 who underwent CPET at the National Amyloidosis Centre...
March 6, 2024: JAMA Cardiology